检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王琼[1] 庞迎旭 米瑞华[2] 尹青松[2] WANG Qiong;PANG Yingxu;MI Ruihua;YIN Qingsong(Department of Hematology,Zhoukou Central Hospital,Zhoukou 466000,Henan Province,China;Department of Hematology,Henan Cancer Hospital,Zhengzhou 450000,Henan Province,China)
机构地区:[1]周口市中心医院血液科,河南周口466000 [2]河南省肿瘤医院血液科,河南郑州450000
出 处:《新乡医学院学报》2023年第7期648-652,共5页Journal of Xinxiang Medical University
摘 要:目的探讨程序性死亡受体1抑制剂卡瑞利珠单抗治疗霍奇金淋巴瘤的近期疗效及安全性。方法选择2017年1月至2020年5月在周口市中心医院接受多柔比星+博来霉素+长春新碱+达卡巴嗪(ABVD)一线化学治疗方案治疗失败的84例霍奇金淋巴瘤患者为研究对象,根据治疗方法将患者分为对照组(n=50)和观察组(n=34)。对照组患者接受表柔比星+长春地辛+达卡巴嗪化学治疗,观察组患者接受卡瑞利珠单抗治疗。比较2组患者化学治疗4个周期后的临床疗效、不良反应发生情况及随访2 a内生存情况。结果化学治疗4个周期后,观察组患者的疾病控制率和客观缓解率显著高于对照组(χ^(2)=4.019、11.213,P<0.05)。治疗期间,观察组患者血液系统毒性Ⅰ~Ⅱ级发生率及非血液系统毒性Ⅲ~Ⅳ级发生率显著低于对照组(P<0.05)。对照组患者Ⅲ级以上不良反应中血液系统毒性占10.00%,非血液系统毒性占18.00%;观察组患者Ⅲ级以上不良反应中仅发现有中性粒细胞减少和肝功能异常,各占2.94%。随访2 a内,对照组患者死亡12例(24.00%),观察组患者死亡2例(5.88%);观察组患者的病死率显著低于对照组(χ^(2)=4.783,P<0.05)。结论卡瑞利珠单抗治疗ABVD方案治疗失败的霍奇金淋巴瘤可增强近期抗肿瘤效果,提高患者生存率,且安全性较高。Objective To investigate the short-term efficacy and safety of Carelizumab of a programmed cell death 1 inhibitor in the treatment of Hodgkin′s lymphoma.Methods A total of 84 patients with Hodgkin′s lymphoma who failed to receive the first-line doxorubicin+bleomycin+vincristine and dacarbazine(ABVD)regimen in Zhoukou Central Hospital from January 2017 to May 2020 were selected as the study subjects,and they were divided into the control group(n=50)and the observation group(n=34)according to treatment methods.The patients in the control group received epirubicin+vindesine+dacarbazine regimen,and the patients in the observation group received Carelizumab.The clinical efficacy after 4 cycles of chemotherapy,adverse reactions and survival within 2 years of follow-up were compared between the two groups.Results After 4 cycles of chemotherapy,the disease control rate and objective remission rate of patients in the observation group were significantly higher than those in the control group(χ^(2)=4.019,11.213;P<0.05).During the treatment,the incidence of gradeⅠ-Ⅱhematological toxicity and gradeⅢ-Ⅳnon-hematological toxicity of patients in the observation group were significantly lower than those in the control group(P<0.05).The hematological toxicity accounted for 10.00%and the non-hematological toxicity accounted for 18.00%of the adverse reactions above gradeⅢin the control group;only neutropenia and abnormal liver function in the adverse reactions above gradeⅢwere found in the observation group,which accounted for 2.94%,respectively.During 2-year follow-up,12 patients(24.00%)in the control group died,while 2 patients(5.88%)in the observation group died;the mortality of patients in the observation group was significantly lower than that in the control group(χ^(2)=4.783,P<0.05).Conclusion Carelizumab can enhance the short-term anti-tumor effect and improve the survival rate of patients with Hodgkin′s lymphoma who failed to ABVD regimen,and it has high safety.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.38